Source: ERS Course 2021 - COVID-19: State of the art



Rating:

Share or cite this content

Citations should be made in the following way:
A. Lyon (London, United Kingdom). Cardiovascular diseases and COVID-19. ERS Course 2021 - COVID-19: State of the art

Member's Comments

No comment yet.

Related content which might interest you: Cardiovascular disease in COPD Source: Eur Respir Monogr 2020; 88: 47-65 Year: 2020 Cardiac diseases Source: ERS Online Course 2016 Year: 2016 Cardiovascular disease and complex OSA Source: Annual Congress 2009 - PG21 Morbidity and mortality of sleep-disordered breathing: jointly organised with ACCP Year: 2009 Smoking risk in cardiovascular and cerebrovascular diseases Source: International Congress 2016 – Smoking-related diseases Year: 2016 Cardiovascular patients Source: Eur Respir Monogr 2021; 90: 208-228 Year: 2021 Cardiovascular assessment Source: International Congress 2014 – PG13 Assessment of the obstructive sleep apnoea patient Year: 2014 Respiratory diseases Source: ERS Online Course 2016 Year: 2016 Respiratory diseases and COVID-19 Source: ERS Course 2021 - COVID-19: State of the art Year: 2021 Pulmonary Hypertension and cardiovascular disease in ILDs Source: School Course 2014 - Interstitial lung diseases Year: 2014 Infectious diseases Source: Annual Congress 2004 - Paediatric year in review Year: 2004 Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases Source: Eur Respir Monogr 2020; 88: 167-183 Year: 2020 Cardiovascular complications and comorbidities in CAP Source: Eur Respir Monogr 2014; 63: 256-254 Year: 2014 Lung complications of neuromuscular diseases Source: Eur Respir Monogr 2019; 86: 278-295 Year: 2019 Cardiovascular disease: pathophysiological mechanisms Source: Eur Respir Monogr 2015; 67: 37-50 Year: 2015 Epidemiological aspects of cardiovascular and respiratory diseases Source: Eur Respir Monogr 2020; 88: 1-11 Year: 2020